Rezolute, Inc.: Revision history

20 August 2022

• curprev 15:3615:36, 20 August 2022 95.149.241.133 talk 768 bytes +11 No edit summary undo

13 August 2022

• curprev 23:4323:43, 13 August 2022 109.180.50.163 talk 757 bytes +15 No edit summary undo

31 July 2022

• curprev 02:1702:17, 31 July 2022 >Chris 742 bytes +742 Created page with "Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in..."